Axitinib showing promise for rcc

November 1, 2007

A new drug from Pfizer has demonstrated positive results in Phase II trials in the U.S.

Phase III trials are open in the U.S. and some sites in Canada. Axinitib is being studied as a 2nd line treatment for mrcc (clear cell) versus sorafenib (Nexavar)

For more information about Axinitib:

http://www.medpagetoday.com/HematologyOncology/OtherCancers/tb/7151

Clinical trial information is available at www.clinicaltrials.gov (search for Axitinib).

Back to news listings
comments powered by Disqus